EDAP TMS S.A. Announces Reimbursement Of HIFU Treatment For Prostate Cancer By France's Ministry Of Health

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LYON, France, April 21, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the reimbursement of prostate cancer treatment procedures using High Intensity Focused Ultrasound ("HIFU") by the French health authorities. The French Minister of Social Affairs and Health outlined the acceptance of HIFU treatment for prostate cancer for reimbursement during a visit to the Company's headquarters on April 18, 2014. Such reimbursement is part of an innovative process to further validate breakthrough therapies and to accelerate reimbursement process based on clinical trials and data registries.

Help employers find you! Check out all the jobs and post your resume.

Back to news